PMID- 26721008
OWN - NLM
STAT- MEDLINE
DCOM- 20160202
LR  - 20181202
IS  - 1025-9589 (Print)
IS  - 1025-9589 (Linking)
VI  - 27
IP  - 3
DP  - 2015 Jul-Sep
TI  - EFFICACY OF 5 MG AND 10 MG ROSUVASTATIN IN TYPE-2 DIABETES MELLITUS WITH 
      HYPERCHOLESTEROALEMIA.
PG  - 564-8
AB  - BACKGROUND: Coronary Heart Disease (CHD) is the most important complication and 
      the leading cause of death in patients with type 2 diabetes mellitus (T2DM). 
      Hypercholesterolemia is an important modifiable risk factor for CHD. Statins are 
      the first line drugs for the treatment of hypercholesterolemia in DM. Comparative 
      studies between different statins are available but different doses of the same 
      statin have not been compared in our population. The objective of this study is 
      to compare mean reduction in serum LDL-C level after using 5mg and 10mg of 
      rosuvastatin among T2DM patients with hypercholesterolemia. This study will help 
      finding lowest effective dose of rosuvastatin to achieve internationally set low 
      density lipoprotein cholesterol (LDL-C) goals. METHODS: A total of 82 patients 
      with T2DM having fasting LDL-C levels equal or more than 100mg/dl were randomly 
      allocated into two groups with 41 patients in each group. Baseline fasting serum 
      LCL-C levels were obtained in all patients. Group A received 5mg while group B 
      received 10mg of rosuvastatin daily at night. After 6 weeks, fasting LDL-C levels 
      were obtained and analysed to compare the mean+/-SD reduction of LDL-C levels in 
      both groups. RESULTS: Baseline mean+/-SD LDL-C levels in group A and group B were 
      134.12+/-30.02 and 143.49+/-32.01 respectively (p 0.176). Follow up mean+/-SD LDL-C 
      levels were 81.59+/-28.47 and 83.24+/-36.06respectively (p 0.818). Mean+/-SD reduction 
      in LDL-C levels from baseline levels in group A and group B were 52.51+/-19.49 and 
      60.20+/-24.09 (p 0.116). CONCLUSION: Rosuvastatin 5mg is as effective as 10mg in 
      reducing the LDL-C levels in type 2 diabetic patients with hypercholesterolemia.
FAU - Ullah, Fahim
AU  - Ullah F
FAU - Afridi, Ayesha Khan
AU  - Afridi AK
FAU - Rahim, Fawad
AU  - Rahim F
FAU - ur Rahman, Saddiq
AU  - ur Rahman S
FAU - Ashfaq, Muhammad
AU  - Ashfaq M
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Pakistan
TA  - J Ayub Med Coll Abbottabad
JT  - Journal of Ayub Medical College, Abbottabad : JAMC
JID - 8910750
RN  - 0 (Cholesterol, LDL)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 83MVU38M7Q (Rosuvastatin Calcium)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Cholesterol, LDL/*blood/drug effects
MH  - Coronary Artery Disease/epidemiology/etiology/*prevention & control
MH  - Diabetes Mellitus, Type 2/blood/*complications
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage
MH  - Hypercholesterolemia/blood/complications/*drug therapy
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Pakistan/epidemiology
MH  - Risk Factors
MH  - Rosuvastatin Calcium/*administration & dosage
MH  - Survival Rate/trends
MH  - Treatment Outcome
EDAT- 2016/01/02 06:00
MHDA- 2016/02/03 06:00
CRDT- 2016/01/02 06:00
PHST- 2016/01/02 06:00 [entrez]
PHST- 2016/01/02 06:00 [pubmed]
PHST- 2016/02/03 06:00 [medline]
PST - ppublish
SO  - J Ayub Med Coll Abbottabad. 2015 Jul-Sep;27(3):564-8.